Neuropsychiatric Drug Development on October 10-12, 2023 in Boston, United States

2023 is booming with novel psychiatric R AND D and the promise of precision medicine for neuropsychiatric patients. Pipelines are gaining momentum, with notable approvals on the horizon, as unmet needs in PTSD, bipolar, anxiety, schizophrenia, depression, and ADHD become greater and greater. There is, therefore, a huge deal of novel and promising research to be discussed this October at the 6th Neuropsychiatric Drug Development Summit.

With discovery, preclinical, translational, and clinical scientists from the likes of Biogen, Otsuka, AbbVie, Genentech, Lundbeck, Delix Therapeutics, Atai, Gilgamesh, and Cerevel Therapeutics, don't miss the field's favorite conference, specifically dedicated to biopharma's most pressing challenges of de-risking the translational gap and advancing transformative neuropsychiatric candidates through the clinic.

URLs:

Tickets: https://go.evvnt.com/1799147-2?pid=10008

Brochure: https://go.evvnt.com/1799147-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Drug Developer Pricing - Conference + 2 Workshops: USD 3597.00,

Drug Developer Pricing - Conference + 1 Workshop: USD 3098.00,

Drug Developer Pricing - Conference Only: USD 2599.00,

Solution Provider Pricing - Conference + 2 Workshops: USD 5297.00,

Solution Provider Pricing - Conference + 1 Workshop: USD 4548.00,

Solution Provider Pricing - Conference Only: USD 3799.00

Speakers: Alberto Cucca, Neurologist, Clinical Specialist, Lundbeck, Alex Nivorozhkin,Chief Scientific Officer, Cybin Inc, Andrew Kruegel, CSO and Co-Founder, Gilgamesh Pharmaceutical, Ayan Ghoshal, Head of Neural Circuits Lab, Biogen, Christian Schubert, Head of AbbVie Ventures, Abbvie, Darrick Balu, Director, Drug Discovery, Entheos Labs, Dino Dvorak, Senior Director, Data Science and Platform Technologies, Gilgamesh Pharmaceutical, Douglas Turk, Business Unit Manager, Eurofins, Edward Christian, Executive Director - Clinical Sciences, Gilgamesh Pharmaceutical, Eli Stahl, Director of Statistical Genetics, Regeneron Pharmaceuticals Inc, Eliseo Salinas, Head of Research and Development, Delix Therapeutics, Esther Hagai, Chief Medical Officer, Clexio Biosciences, Gina Pastino, Senior Director, Clinical Pharmacology, Cerevel Therapeutics, Hailey Gilmore, Medical Science Liaison, MAPS Public Benefit Corp., Hajira Koeller, Senior Director - Clinical Scientist, BioXcel Therapeutics, Ishrat Husain, Associate Professor, Clinician-Investigator, Department of Psychiatry, University of Toronto, Jackie Von Salm, Co-Founder and CSO, Psilera Bioscience, Jadwiga Martynowicz, President Neokee Pharama Consulting, LLC, ATAI Life Sciences, James Rawls, Vice President and Head Of Global Regulatory Affairs, Chair, Diversity and Inclusion Council, Sunovion, Jen Pan, Associate Director - Translational Neurobiology, The Broad Institute of MIT and Harvard, Julie Adams, Executive Director - Medical, Abbvie, Kaitlin Roberson, CEO, Cacti Therapeutics, Kevin Lanzo, Lead Scientist - Clinical Psychiatry, Genentech, Kevin Sanders, Global Head of Psychiatry and Neurodevelopment, Genentech, Kimberly Babson, Senior Director Clinical Development, Neuroscience and Global Clinical Lead JZP150, Jazz Pharmaceuticals Inc, Laura Perez-Cano, Head of Discovery, Stalicla S.A., Lynn Marie Morski, President (Psychedelic Medicine Association), Host (Psychedelic Medicine Podcast), Clinical Advisory Board member (Cybin), Psychedelic Medicine Association, Lynn-Allison Durham, Chief Executive Officer and Founder, Stalicla, Matthew Baggott, Co-Founder and Chief Executive Officer, Tactogen Inc, Michael Didriksen, Senior Director, Lundbeck, Michael McCully, President and CEO, Gate Neurosciences, Inc., Michael Palfreyman, Chief Research and Development Officer, Cybin Inc, Paolo Cassano, Director of Photobiomodulation (Division of Neuropsychiatry at Mass General Hospital), Harvard Medical School, Saloni Behl, Senior Director - Neuroscience and Global Development Team Leader, Otsuka, Scott Kollins, Chief Medical Officer, Akili, Tanweer Khan, Directror, Head of Discovery Chemistry, ATAI Life Sciences, Yael Mandelblat-Cerf, Chief, Molecular and Cellular Neuroscience Branch, Division of Neuroscience and Basic Behavioral Science, National Institute of Mental Health